STC2 Antibody

1. MiR-184 was confirmed to directly target STC2 in glioblastoma cells PMID: 28887636
2. Results show that STC2 promotes head and neck squamous cell carcinoma cell proliferation, tumor growth, and metastasis through the PI3K/AKT/Snail pathway. PMID: 27863406
3. STC2 promotes colorectal cancer tumorigenesis and epithelial-mesenchymal transition (EMT) progression through activating ERK/MEK and PI3K/AKT signaling pathways. PMID: 27662663
4. Our results demonstrated the contrasting effects of STC1 and STC2-derived peptides on human macrophage foam cell formation associated with ACAT1 expression and on HASMC migration. PMID: 27346255
5. Mus81 knockdown suppresses proliferation and survival of HCC cells likely by downregulating STC2 expression, implicating Mus81 as a therapeutic target for HCC. PMID: 27939696
6. These findings indicated that STC2 may promote osteoblast differentiation and mineralization by regulating ERK activation PMID: 27878259
7. STC2 is involved in regulating PAPP-A activity during the development of atherosclerosis PMID: 26983002
8. Data suggest that stanniocalcin 1 and 2 (STC1, STC2) participate in inhibition of proteolytic activity of pregnancy-associated plasma protein-A (PAPP-A) during folliculogenesis. PMID: 26874357
9. Up-regulation of CDK2 and CDK4 and down-regulation of cell cycle inhibitors p16 and p21 were observed after the delivery of STC2. Furthermore, STC2 transduction activated pAKT and pERK 1/2 signal pathways. PMID: 26424558
10. This study utilized ER+ IBC to identify a metagene including ABAT and STC2 as predictive biomarkers for endocrine therapy resistance. PMID: 25771305
11. STC2 may inhibit epithelial-mesenchymal transition at least partially through the PKC/Claudin-1-mediated signaling in human breast cancer cells. PMID: 25830567
12. STC2 has a role in promoting cell proliferation and cisplatin resistance in cervical cancer PMID: 26361149
13. The aim of this study was to evaluate the clinical value of measuring expression levels of STC2 in colorectal cancer (CRC) patients. PMID: 25234931
14. Stanniocalcin 2 may contribute to tumor development and radioresistance in cervical cancer. PMID: 25674244
15. These findings suggest that STC2 can be a potential lung cancer biomarker and plays a positive role in lung cancer metastasis and progression. PMID: 25463045
16. Circulating STC1 and STC2 mRNA are potentially useful blood markers for LSCC PMID: 24743310
17. High STC2 expression is associated with glioma. PMID: 24729417
18. Interleukin-1-induced changes in the glioblastoma secretome suggest its role in tumor progression. PMID: 24503185
19. STC2 overexpression correlates to poor prognosis for nasopharyngeal carcinomas. PMID: 24606961
20. stanniocalcin 2 (STC2) was the most highly upregulated gene in anti-VEGF antibody-treated tumors PMID: 24375080
21. Our results indicate that STC2 could be a useful molecular blood marker for predicting tumor progression by monitoring CTCs in patients with gastric cancer. PMID: 24100594
22. Stanniocalcin-1 and -2 promote angiogenic sprouting in HUVECs via VEGF/VEGFR2 and angiopoietin signaling pathways. PMID: 23664860
23. High STC2 expression levels are associated with disease recurrence in patients with gastric cancer. PMID: 23548070
24. High STC2 expression is associated with lymph node metastasis in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. PMID: 23906305
25. STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration. PMID: 23187001
26. These findings point to three novel functions of STC2, and suggest that STC2 interacts with HO1 to form a eukaryotic 'stressosome' involved in the degradation of heme. PMID: 22503972
27. High STC2 is associated with lymph node metastases in squamous cell esophageal carcinoma. PMID: 20734150
28. Human stanniocalcin-1 or -2 expressed in mice reduces bone size and severely inhibits cranial intramembranous bone growth. PMID: 20174869
29. High expression level of Stanniocalcin 2 is associated with gastric cancer. PMID: 20422456
30. STC2 is a positive regulator in tumor progression at hypoxia. PMID: 20619259
31. STC2 is a HIF-1 target gene and is involved in the regulation of cell proliferation. PMID: 19786016
32. STC-2 can act as a potent growth inhibitor and reduce intramembranous and endochondral bone development and skeletal muscle growth, implying that these tissues are specific physiological targets of stanniocalcins PMID: 15367391
33. Recombinant human and fish STC2 proteins were generated and found to be N-glycosylated homodimers. STC2 is a functional homodimeric glycoprotein, and thecal cell-derived STC2 could play a paracrine role during follicular development. PMID: 15486227
34. NTN4, TRA1, and STC2 have roles in progression of breast cancer PMID: 17545519
35. The induction of GDF15 and STC2 is likely specific to MK-4, vitamin K2 analog. PMID: 17909264
36. elevated expression of STC-1 or STC-2 act as survival factors also for breast cancer cells and thereby contribute to tumor dormancy. PMID: 18355956
37. STC2 was aberrantly hypermethylated in human cancer cells. PMID: 18394600
38. Stanniocalcin 2 expression is regulated by hormone signalling and negatively affects breast cancer cell viability in vitro. PMID: 18492817
39. stanniocalcin 2 overexpression in a prostate cancer cell line promoted prostate cancer cell growth, indicating its oncogenic property PMID: 19298603
40. Increased STC2 gene expression is associated with colorectal cancer. PMID: 19415750
41. Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma. PMID: 19582875

Show More

Hide All

HGNC: 11374

OMIM: 603665

KEGG: hsa:8614

STRING: 9606.ENSP00000265087

UniGene: Hs.233160